Data Science With Sam

Soumava Dey

This is an educational podcast focused on bringing academia and industry experts together in a common forum and initiate discussion geared towards data science, artificial intelligence, actuarial science and scientific research. DISCLAIMER: The views and opinions expressed in this podcast are solely those of the host(s) or guest(s) and do not necessarily reflect the policy or position of any organization. The podcast is intended to provide general educational information and entertainment purposes only.

  1. EP 33: Agents Everywhere: What Agentic AI Actually Means for Your Job

    4日前

    EP 33: Agents Everywhere: What Agentic AI Actually Means for Your Job

    Everyone's talking about agentic AI, but there's a gap between the hype ("AI will do your job for you") and the reality, which is more nuanced and frankly more interesting. The word "agentic" has officially crossed from technical jargon into buzzword territory—simultaneously everywhere and nowhere. Everyone's using it, few can define it precisely. This episode cuts through the noise to explain what agentic AI systems actually are, what they can and cannot do today, and the realistic implications for people working in data, tech, and knowledge work. What is an agent? Traditional AI interaction: you send a prompt, the model produces a response, done. An AI agent is different: it takes a goal, breaks it into steps, takes actions in the world (browsing the web, writing and running code, calling APIs, managing files), observes results, and iterates until the goal is achieved or it gets stuck. The key agentic feature: it operates across multiple steps autonomously without you manually directing each one. Examples include OpenAI's Claude (consumer-facing), but in enterprise settings, agents are being deployed for automated customer support escalation, multi-step data pipeline management, code review and testing workflows, and research synthesis across large document sets. What can agents do today in early 2026? Agents are reliable for well-defined, bounded tasks with clear success criteria—taking support tickets, classifying them, drafting responses, flagging uncertain ones for human review. But for autonomously managing complex, open-ended strategic projects? Still unreliable. Failure modes include hallucinations, tool use errors, context window limitations in long tasks, and difficulty recovering gracefully when something unexpected happens mid-task. These are real limitations the best researchers are actively working on. The realistic workforce impact right now is task displacement rather than job displacement. Specific tasks within jobs are being automated: first drafts of documents, initial data analysis, standard code patterns, customer FAQ responses. Higher-order judgment, stakeholder navigation, creative problem framing, and ethical calls remain under human control. For data scientists specifically, repetitive engineering work is most likely to be automated: data cleaning pipelines, standard visualizations, model deployment scripts. But statistical thinking, algorithmic design, understanding model outputs, and evaluating trustworthiness remain human responsibilities. The work becoming more valuable: knowing what questions to ask, evaluating whether AI output is trustworthy, and designing systems that fail safely. The advice: become a power user of agentic tools before your role requires it. Not because you'll be replaced by an agent, but because practitioners who understand these tools deeply will be disproportionately effective. Learn how to prompt agents for complex multi-step tasks, evaluate outputs critically, and understand failure modes so you can deploy humans strategically. Agentic AI is real, useful today for specific tasks, and improving rapidly. The hype is ahead of the reality, but not by as much as you might think.

    8分
  2. EP 32: AI Discovers Drugs: The 2026 Clinical Trial Moment for AI in Biotech

    3月16日

    EP 32: AI Discovers Drugs: The 2026 Clinical Trial Moment for AI in Biotech

    For years, AI in drug discovery has been a promise—billions invested, hundreds of papers published, dozens of startups founded, but actual drugs coming out the other end? Not yet. This is changing in 2026. Several AI-discovered drug candidates are now entering mid-to-late stage clinical trials. This is the year the receipts arrive for AI in drug discovery. The biotech industry is calling 2026 a landmark year. For a sector that's been hyped as much as it's been scrutinized, the fact that we're finally getting real clinical data on AI-designed drug candidates is a big deal. Multiple candidates discovered and optimized using AI systems are now in Phase 2 and Phase 3 clinical trials, primarily focused on oncology and rare diseases—areas where existing options are limited and financial incentives for innovation are high. Companies furthest along include Insilico Medicine, Recursion Pharmaceuticals, and Exscientia. Their drug candidates were identified by AI systems analyzing massive biological datasets and predicting molecular structures likely to interact with disease targets in useful ways. What used to take teams of medicinal chemists years to accomplish, these systems can explore in weeks—a massive boost for clinical trial phases by reducing R&D time. Why this matters: Traditional drug discovery takes 10-15 years and over $1 billion per approved drug. Most candidates fail—the attrition rate in clinical trials is brutal. AI's promise is dramatically improving the hit rate by better predicting which candidates will actually work before spending money on trials. Even a modest improvement in clinical trial success rates would have enormous downstream impact on human health. But 2026 is a stress test. Clinical trials expose whether AI-predicted drug behavior holds up in actual human biology, which is extraordinarily complex. AI models are trained on known data; when candidates reach trials, you're testing the model's ability to generalize to real biological complexity that wasn't in training. Early signals have been mixed—some candidates performing well, others hitting unexpected toxicity issues. The honest answer: we don't know yet how much AI improves success rates at the clinical stage. For data scientists interested in this space, the most interesting current work is in molecular property prediction, protein structure modeling building on AlphaFold, and multi-objective optimization across efficacy, safety, and synthesizability simultaneously. Recursion's operating system approach treats drug discovery as a data problem end-to-end—one of the most ambitious attempts to apply ML infrastructure thinking to biology at scale. AI in drug discovery is no longer just a story about potential—it's now a story about evidence. The next two years of clinical data will either validate or seriously challenge what's been claimed.

    8分
  3. EP 27: AI and the Creative Arts: Innovation or Appropriation?

    2025/11/25

    EP 27: AI and the Creative Arts: Innovation or Appropriation?

    Can a machine create art? Should it? And if it does, who owns it? In this episode, I sit down with Andres—creative technologist, founder of Red Mage, and advocate for equitable AI—to tackle one of the most controversial conversations in tech right now: AI's role in creative industries. What we discuss: ✅ How generative AI has transformed creativity in just two years ✅ The copyright battleground: Should AI companies compensate artists? ✅ Authenticity vs. automation: Does the creative process matter? ✅ What AI fundamentally CANNOT replicate about human creativity ✅ The displacement reality: Are creative professionals being replaced? ✅ AI as collaborator vs. competition: Success stories and cautionary tales ✅ Democratization or devaluation? The debate over accessible creative tools ✅ Maintaining quality when the internet is flooded with AI content ✅ Ethical concerns beyond copyright: deepfakes, cultural appropriation, environmental costs ✅ The future landscape: Will "human-made" labels matter in 2029? 📌 If this conversation resonates with you, please like, subscribe, and share. Let me know in the comments: Are you optimistic or concerned about AI in creative industries? 🔗 Connect with Andres: LinkedIn: https://www.linkedin.com/in/andres-sepulveda-morales/ Contra: https://contra.com/andersthemagi/work?r=andersthemagi Sessionize: https://sessionize.com/andersthemagi/ 🔗 Connect with me: DataScienceWithSam on YouTube LinkedIn: https://www.linkedin.com/in/soumava-dey-441294ab/

    55分

番組について

This is an educational podcast focused on bringing academia and industry experts together in a common forum and initiate discussion geared towards data science, artificial intelligence, actuarial science and scientific research. DISCLAIMER: The views and opinions expressed in this podcast are solely those of the host(s) or guest(s) and do not necessarily reflect the policy or position of any organization. The podcast is intended to provide general educational information and entertainment purposes only.

その他のおすすめ